Why UnitedHealth’s Massive Bottom-Line Beat Doesn’t Matter

Photo of Chris Lange
By Chris Lange Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Why UnitedHealth’s Massive Bottom-Line Beat Doesn’t Matter

© Courtesy of UnitedHealth Group

When UnitedHealth Group Inc. (NYSE: UNH | UNH Price Prediction) released its second-quarter financial results before the markets opened on Wednesday, the firm posted $7.12 in earnings per share (EPS) and $62.1 billion in revenue. Analysts were calling for EPS of $5.18 on $63.43 billion in revenue. In the same period of last year, UnitedHealth said it had $3.60 in EPS and revenue of $60.59 billion.

Earnings were substantially higher than anticipated this quarter due primarily to the unprecedented, temporary deferral of care in the company’s risk-based businesses. However, management was quick to say that this likely will be offset in the quarters ahead.

During the latest quarter, total revenues grew $4.1 billion, or 6.8%, year over year, reflecting balanced, broad-based revenue growth across Optum and UnitedHealthcare.

UnitedHealthcare revenues increased 2.5% year over year to $62.1 billion. Second-quarter earnings from operations at UnitedHealthcare were $9.2 billion, nearly double from the same period last year.

[nativounit]

Optum second-quarter revenues and operating earnings of $32.7 billion and $2.2 billion, respectively, increased from $28.0 billion and $2.1 billion a year ago. This was led by earnings growth at OptumHealth.

Looking ahead, the company maintained its outlook for the 2020 full year. Currently, UnitedHealth expects to see EPS in the range of $16.25 to $16.55. Consensus estimates call for $16.29 in EPS and $258.69 billion in revenue for the full year.

On the books, the company ended the quarter with $25.59 billion in cash and cash equivalents, up from $14.25 billion at the end of 2019.

UnitedHealth stock traded down about 2% to $302.68 early Wednesday, in a 52-week range of $187.72 to $315.84. The consensus price target is $332.44.

[recirclink id=723711][wallst_email_signup]

Photo of Chris Lange
About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618